罚单大砍 95% 后金城医药实控人再申诉，其父立案前套现4000多万

Core Viewpoint - The recent announcement from Jincheng Pharmaceutical (300233.SZ) regarding the administrative penalties against its actual controller and chairman Zhao Yeqing has significantly altered market expectations, with the proposed fines being reduced by 95% compared to earlier estimates [1][9]. Group 1: Administrative Penalties - The China Securities Regulatory Commission (CSRC) has issued a second administrative penalty notice proposing a total fine of 3 million yuan, with Zhao Yeqing responsible for 1.5 million yuan, Wang Zhen for 1.2 million yuan, and Liu Feng for 300,000 yuan [1]. - The initial penalty proposal was much harsher, totaling 61.76 million yuan, which included confiscation of illegal gains [5][9]. - Zhao Yeqing has chosen to continue appealing the decision, indicating that the 3 million yuan fine is not yet finalized [1][9]. Group 2: Market Reaction and Stock Performance - Following the announcement of the investigation into Zhao Yeqing for alleged market manipulation, Jincheng Pharmaceutical's stock price dropped significantly, falling 16.9% on the first trading day after the news [3]. - The stock continued to decline, reaching a low of 10.8 yuan per share [3]. - As of the latest closing, the stock price was 18.84 yuan per share, reflecting a 2.22% increase, with a market capitalization of 7.2 billion yuan [5]. Group 3: Company Financial Performance - Jincheng Pharmaceutical's financial performance has been unstable, with a slight revenue increase of 0.93% in 2023, but a significant net profit decline of 36.09% [6]. - For the first half of 2025, the company reported a revenue of 1.36 billion yuan, a decrease of 22.65%, and a net profit of 43.38 million yuan, down 66.78% year-on-year [8]. - The decline in cash flow from operating activities was attributed to decreased sales and reduced collections, with a net cash flow of 104 million yuan, down 40.34% [8]. Group 4: Shareholding Structure - Zhao Yeqing and his father Zhao Hongfu are the actual controllers of Jincheng Pharmaceutical, with respective direct holdings of 1.88% and 1.74%, and an additional 20.46% through Jincheng Industrial [5]. - The combined market value of their holdings is approximately 1.742 billion yuan [5].